LON:ROQ Roquefort Therapeutics (ROQ) Share Price, News & Analysis GBX 3.92 +0.02 (+0.59%) (As of 12/20/2024 11:17 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider Trades About Roquefort Therapeutics Stock (LON:ROQ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Roquefort Therapeutics alerts:Sign Up Key Stats Today's Range 3.80▼ 4.0850-Day Range 3.50▼ 6.5052-Week Range 3.30▼ 9.50Volume520,577 shsAverage Volume602,056 shsMarket Capitalization£5.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewRoquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action. Roquefort Therapeutics plc was incorporated in 2020 and is based in London, the United Kingdom.Read More… Receive ROQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roquefort Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ROQ Stock News HeadlinesRoquefort Therapeutics (LON:ROQ) Shares Down 3.3% - Should You Sell?December 18, 2024 | americanbankingnews.comGlycoMimetics, Inc. (GKO.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.December 22, 2024 | Brownstone Research (Ad)Roquefort Therapeutics says MK cell therapy patent approved in JapanSeptember 24, 2024 | lse.co.ukTG Therapeutics, Inc. (TGTX)August 10, 2024 | finance.yahoo.comRoquefort Therapeutics PLC ROQMay 29, 2024 | morningstar.comEARNINGS AND TRADING: Aura confident in Tiris; Cindrigo enters GermanyApril 26, 2024 | lse.co.ukUK Stocks: Here’s Why Roquefort (ROQ) Share Price is CrashingApril 5, 2024 | msn.comSee More Headlines ROQ Stock Analysis - Frequently Asked Questions How have ROQ shares performed this year? Roquefort Therapeutics' stock was trading at GBX 7.25 on January 1st, 2024. Since then, ROQ shares have decreased by 45.9% and is now trading at GBX 3.92. View the best growth stocks for 2024 here. How do I buy shares of Roquefort Therapeutics? Shares of ROQ stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Roquefort Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Roquefort Therapeutics investors own include Vislink Technologies (XGTI), AutoZone (AZO), Intel (INTC), Premier African Minerals (PREM), Rolls-Royce Holdings plc (RR), TJX Companies (TJX) and Abacus Health Products (ABAHF). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:ROQ CUSIPN/A CIKN/A Webwww.roquefortinvest.com Phone44 20 3290 9339FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-1,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-27.05% Return on Assets-15.86% Debt Debt-to-Equity Ratio12.37 Current Ratio0.79 Quick Ratio3.07 Sales & Book Value Annual Sales£637.00 Price / Sales7,953.77 Cash FlowGBX 2.62 per share Price / Cash Flow1.49 Book ValueGBX 4 per share Price / Book0.98Miscellaneous Outstanding Shares129,150,000Free FloatN/AMarket Cap£5.07 million OptionableNot Optionable Beta0.05 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (LON:ROQ) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roquefort Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Roquefort Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.